Xspray Pharma AB (publ)

OM:XSPRAY Stock Report

Market Cap: SEK 1.6b

Xspray Pharma Future Growth

Future criteria checks 5/6

Xspray Pharma is forecast to grow earnings and revenue by 134.8% and 135.6% per annum respectively while EPS is expected to grow by 126.8% per annum.

Key information

134.8%

Earnings growth rate

126.8%

EPS growth rate

Biotechs earnings growth42.6%
Revenue growth rate135.6%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Nov 2024

Recent future growth updates

Recent updates

We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

Feb 25
We Think Xspray Pharma (STO:XSPRAY) Needs To Drive Business Growth Carefully

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

May 11
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

Feb 01
We Think Xspray Pharma (STO:XSPRAY) Can Afford To Drive Business Growth

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Oct 26
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

Jun 20
We're Not Very Worried About Xspray Pharma's (STO:XSPRAY) Cash Burn Rate

We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Mar 19
We're Hopeful That Xspray Pharma (STO:XSPRAY) Will Use Its Cash Wisely

Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Feb 12
Do Institutions Own Xspray Pharma AB (publ) (STO:XSPRAY) Shares?

Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Dec 04
Here's Why We're Watching Xspray Pharma's (STO:XSPRAY) Cash Burn Situation

Earnings and Revenue Growth Forecasts

OM:XSPRAY - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,618818N/AN/A2
12/31/2025498-60-154-602
12/31/20242-216-283-1982
9/30/2024N/A-258-232-193N/A
6/30/2024N/A-215-259-221N/A
3/31/2024N/A-213-257-213N/A
12/31/2023N/A-180-256-203N/A
9/30/2023N/A-180-268-206N/A
6/30/2023N/A-170-242-160N/A
3/31/2023N/A-148-223-128N/A
12/31/2022N/A-132-238-110N/A
9/30/2022N/A-128-216-85N/A
6/30/2022N/A-114-198-79N/A
3/31/2022N/A-102-185-67N/A
12/31/2021N/A-97-148-52N/A
9/30/2021N/A-60-146-53N/A
6/30/2021N/A-57-145-49N/A
3/31/2021N/A-56-141-46N/A
12/31/2020N/A-52-141-48N/A
9/30/2020N/A-56-141-48N/A
6/30/2020N/A-55-140-44N/A
3/31/2020N/A-49-135-35N/A
12/31/2019N/A-46-126-34N/A
9/30/2019-22-41-115-29N/A
6/30/2019-14-34-97-24N/A
3/31/2019-6-30-91-27N/A
12/31/20180-23-65-18N/A
9/30/201831-17-62-25N/A
6/30/201828-16N/A-12N/A
3/31/201829-8N/A-7N/A
12/31/20170-14N/A-12N/A
9/30/2017351N/A12N/A
6/30/201730-3N/A-2N/A
3/31/201721-7N/A-6N/A
12/31/201621-4N/A-2N/A
12/31/20155-12N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: XSPRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).

Earnings vs Market: XSPRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: XSPRAY is expected to become profitable in the next 3 years.

Revenue vs Market: XSPRAY's revenue (135.6% per year) is forecast to grow faster than the Swedish market (1.2% per year).

High Growth Revenue: XSPRAY's revenue (135.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XSPRAY's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 11:26
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xspray Pharma AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dan AkschutiPareto Securities
Filip EinarssonRedeye